ReviewFrontiers in oncology2025
Merkel cell polyomavirus in lung carcinogenesis: evidence and controversy.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Respiratory Models Reveal DNA Damage Response Modulation by Merkel Cell Polyomavirus.International journal of molecular sciences · 2026Article
- In vitro evaluation of bidirectional transcription levels of five types of non-coding control regions of Merkel cell polyomavirus.Virology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) has been recognized as the leading cause of cancer mortality on a global scale. Although tobacco smoking is predominantly associated with LC (~85%), approximately 15-25% of lung cancers occur in non-smokers. This suggests that other biological cofactors, such as chronic infection and inflammation, are responsible for lung carcinogenesis. Due to the histological similarities between LC and Merkel cell polyomavirus (MCPyV)-associated Merkel cell carcinoma (MCC), studies have investigated their association, particularly small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). However, the association between MCPyV infection and LC has been controversial due to inconsistent clinical findings in limited number of cases. To our knowledge, MCPyV is generally ubiquitous and maintains lifelong latent infections in immunocompetent individuals. Thus, its association with high-morbidity cancers raised concerns, and controversy about its cellular tropism as well. Further research is needed to elucidate the pathways by which MCPyV participates the development and progression of LC. Moreover, understanding the role of MCPyV in LC may lead to novel therapeutic strategies. In this review, we critically evaluate the available evidence for and against the aetiological association of MCPyV and LC to help understand its aetiological role, which will provide valuable insights for the diagnosis and therapy of LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.